RxDoctor Payments Data

Kristi West, APRN

Psychiatric/Mental Health · Moncks Corner, SCNPI 1245273663

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.4% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Johnson & Johnson at 29.2% of the total.

$3,090in general payments, 2019–2025

Across 185 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$901
  • Teva Pharmaceuticals USA, Inc.$464
  • Alkermes, Inc.$387
  • Neurocrine Biosciences, Inc.$365
  • Otsuka America Pharmaceutical, Inc.$339
  • Lundbeck LLC$173
  • plus $461 from 9 others

What the payments were for

  • Food & beverage$2,97996%
  • Education$1114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,090 in reported general payments places this provider in the 80th percentile of 354 psychiatric/mental health providers in South Carolina.

See all psychiatric/mental health providers in South Carolina

Medicare billing

Part B allowed, 2024
$1,474
Medicare patients
14
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine126$773,949
Invega SustennaPaliperidone Palmitate97$315,869
Invega TrinzaPaliperidone Palmitate35$277,513
Abilify MaintenaAripiprazole90$251,227
AristadaAripiprazole Lauroxil55$168,643
NuplazidPimavanserin Tartrate13$53,251
VraylarCariprazine Hcl26$39,976
UzedyRisperidone12$24,129
Lurasidone Hcl42$11,206
Hydroxyzine Hcl248$8,792
Paliperidone ErPaliperidone29$5,173
Aripiprazole109$5,079
Clozapine84$4,125
Benztropine Mesylate219$3,642
Fluphenazine Hcl33$3,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Uzedy, Loxapine$464$798,554149 claims
Johnson & JohnsonInvega Sustenna, Invega Trinza$901$593,382132 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$339$251,22790 claims
Alkermes, Inc.Aristada$387$168,64355 claims
AbbVieVraylar$57$39,97626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 354 psychiatric/mental health providers in South Carolina.

Other psychiatric/mental health in Moncks Corner

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →